Press Release:

CYTOCHROMA ANNOUNCES APPOINTMENT OF ULRIK SPORK TO BOARD OF DIRECTORS

Markham, Ontario, Canada — October 30, 2008 — Cytochroma today announced the appointment of Ulrik Spork to its Board of Directors.  Mr. Spork will represent Novo A/S on the Company’s Board and replaces Dr. Søren Schifter, who is leaving Novo A/S. The number of Board members remains unchanged at six members.

“We are very pleased to welcome Ulrik Spork to our board and look forward to drawing on his expertise and experiences as we continue building Cytochroma into a leading CKD-focused specialty pharmaceutical company,” stated Alan Lewis, Ph.D., Chairman of Cytochroma’s Board of Directors.  “We would also like to thank Søren Schifter for his advice to Cytochroma over the years, and wish him well in the future.”

Ulrik Spork has significant experience in corporate strategy, business development, M&A, product development, and international marketing. As Senior Partner, he led the establishment of venture investment activities by Novo A/S from its inception in 1999.  Prior to the formation of Novo A/S, Mr. Spork was Director of Corporate Development at Novo Nordisk A/S, during which he was involved in that company’s strategic planning and managed a number of acquisitions. He holds an MSc in Engineering from the Technical University of Copenhagen and a BSc in International Economics.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company’s vitamin D-based therapeutics are designed to safely and effectively treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in these same patients.

For information contact:
Gordon Ngan
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
gordon.ngan@cytochroma.com

Media Inquiries:
Robert Stanislaro (FD)
Tel: +1 (212) 850-5657
robert.stanislaro@fd.com

< go back >